Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Gut microbiota profiling in patients with bone fragility fracture and severe osteoarthritis: A pilot study.

Mechanisms of ageing and development·2026
Same author

Tumor-derived sphingosine-1-phosphate shapes angiogenesis in the acidic microenvironment of osteosarcoma via paracrine and autocrine signaling.

Frontiers in cell and developmental biology·2026
Same author

Automatic computational assessment of bone mineral properties through Fourier transform infrared spectroscopy analysis.

Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy·2026
Same author

The Effects of Immediate Dentin Sealing on the Enzymatic Activity and Bond Strength of Hybrid Ceramic CAD/CAM Onlays: A Comparative Study of Two Universal Adhesives.

Dentistry journal·2026
Same author

Sphingosine-1-Phosphate Promotes FOS Activation in Osteosarcoma Under Tumor Acidosis.

Acta physiologica (Oxford, England)·2026
Same author

Lower Third Molar Germectomy: Timings, Indications, and Clinical and Patient-Reported Outcomes-A Systematic Review and Meta-Analysis.

Dentistry journal·2026

Related Experiment Video

Updated: Jun 3, 2025

Generation of Heterogeneous Drug Gradients Across Cancer Populations on a Microfluidic Evolution Accelerator for Real-Time Observation
10:24

Generation of Heterogeneous Drug Gradients Across Cancer Populations on a Microfluidic Evolution Accelerator for Real-Time Observation

Published on: September 19, 2019

6.3K

A Novel Microfluidic Platform for Personalized Anticancer Drug Screening Through Image Analysis.

Maria Veronica Lipreri1, Marilina Tamara Totaro2, Julia Alicia Boos3

  • 1Biomedical Science, Technologies, and Nanobiotecnology Lab, IRCCS Istituto Ortopedico Rizzoli, 40136 Bologna, Italy.

Micromachines
|January 8, 2025
PubMed
Summary

A new microfluidic device effectively generates patient-derived tumor spheroids for personalized drug screening in osteosarcoma and chondrosarcoma. Doxorubicin significantly reduced spheroid viability, highlighting potential for tailored cancer therapies.

Keywords:
chondrosarcomadrug screeningmicrofluidicsosteosarcomapersonalized medicine

More Related Videos

Clinical Microfluidic Chip Platform for the Isolation of Versatile Circulating Tumor Cells
05:58

Clinical Microfluidic Chip Platform for the Isolation of Versatile Circulating Tumor Cells

Published on: October 13, 2023

1.1K
Microfluidic Device for Recreating a Tumor Microenvironment in Vitro
16:18

Microfluidic Device for Recreating a Tumor Microenvironment in Vitro

Published on: November 20, 2011

11.5K

Related Experiment Videos

Last Updated: Jun 3, 2025

Generation of Heterogeneous Drug Gradients Across Cancer Populations on a Microfluidic Evolution Accelerator for Real-Time Observation
10:24

Generation of Heterogeneous Drug Gradients Across Cancer Populations on a Microfluidic Evolution Accelerator for Real-Time Observation

Published on: September 19, 2019

6.3K
Clinical Microfluidic Chip Platform for the Isolation of Versatile Circulating Tumor Cells
05:58

Clinical Microfluidic Chip Platform for the Isolation of Versatile Circulating Tumor Cells

Published on: October 13, 2023

1.1K
Microfluidic Device for Recreating a Tumor Microenvironment in Vitro
16:18

Microfluidic Device for Recreating a Tumor Microenvironment in Vitro

Published on: November 20, 2011

11.5K

Area of Science:

  • Oncology
  • Biomedical Engineering
  • Cancer Research

Background:

  • Personalized medicine is crucial for treating rare, aggressive cancers like osteosarcoma and chondrosarcoma.
  • Existing drug screening methods may not fully capture patient-specific tumor responses.
  • Need for reliable in vitro models for evaluating novel therapeutic strategies.

Purpose of the Study:

  • To develop and validate a novel PDMS-agarose microfluidic device for generating patient-derived tumor spheroids.
  • To utilize the device for personalized drug screening of anticancer agents.
  • To assess the efficacy of doxorubicin against osteosarcoma and chondrosarcoma spheroids.

Main Methods:

  • Fabrication of a PDMS-agarose microfluidic device for spheroid generation.
  • Generation of patient-derived osteosarcoma and chondrosarcoma spheroids (approx. 300 µm diameter).
  • Drug screening using doxorubicin and a custom imaging index measuring spheroid viability (diameter, calcein AM, binary fraction area).

Main Results:

  • The microfluidic device reliably produced 20 spheroids within 24 hours, enabling reproducible assessments.
  • Doxorubicin treatment (10 µM) decreased spheroid viability by approximately 75% in both osteosarcoma and chondrosarcoma.
  • Osteosarcoma spheroids demonstrated higher sensitivity to doxorubicin compared to chondrosarcoma spheroids within 48 hours.

Conclusions:

  • The developed microfluidic platform offers a reliable in vitro model for aggressive bone sarcomas.
  • This patient-derived spheroid model facilitates personalized drug screening for tailored cancer treatments.
  • The approach shows promise for improving therapeutic strategies despite some implementation challenges.